Dupilumab Shows Promise for Atopic Dermatitis in Skin of Color

The DISCOVER trial (NCT number not available) was a single-arm, open-label study that included 120 patients with AD and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, and 5% Arab, Central American, or other). Participants were treated biweekly with dupilumab using a weight-based dosing regimen.

Atopic dermatitis, characterized by type 2 inflammation, can manifest differently in individuals with skin of color, often presenting as darker patches of hyperpigmentation. This can lead to misdiagnosis and underestimation of disease severity. The study's findings suggest that dupilumab can effectively reduce disease severity, itch, and hyperpigmentation in this population.

Why This Matters: These results are significant because they provide clinical evidence supporting the use of dupilumab in a population that has historically been underserved in atopic dermatitis research and treatment. The improvements in disease severity and itch can significantly enhance the quality of life for individuals with skin of color affected by AD.

Dupixent, a fully human monoclonal antibody, works by inhibiting the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, key drivers of type 2 inflammation. It is not an immunosuppressant.

Atopic dermatitis (eczema) is a chronic skin condition characterized by type 2 inflammation, causing itchiness, redness, and dry skin.

Dupixent is a monoclonal antibody that blocks the signaling of interleukin-4 and interleukin-13 pathways, reducing inflammation.

The trial showed significant improvements in disease severity, itch, and post-inflammatory hyperpigmentation in patients with skin of color treated with Dupixent.

Do you think these findings will change the way atopic dermatitis is treated in people of color? Let us know!

Share this article with others who need to stay ahead of this trend!